Biochemical properties of plasminogen activator inhibitor-1

被引:86
作者
Dupont, Daniel Miotto [1 ,2 ]
Madsen, Jeppe Buur [1 ]
Kristensen, Thomas [1 ]
Bodker, Julie Stove [1 ]
Blouse, Grant Ellsworth [1 ]
Wind, Troels [1 ]
Andreasen, Peter Andre [1 ]
机构
[1] Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus C, Denmark
[2] Univ Aarhus, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus C, Denmark
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2009年 / 14卷
关键词
serpins; PAI-1; Vitronectin; Protein Folding; Latency Transition; Serine Proteases; Fibrinolysis; Endocytosis; Urokinase; uPA; tPA; Cancer; Review; DENSITY-LIPOPROTEIN-RECEPTOR; SOMATOMEDIN-B-DOMAIN; ALPHA-HELIX-F; SERPIN-PROTEASE COMPLEX; REACTIVE-CENTER LOOP; SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING PROPERTIES; NMR SOLUTION STRUCTURE; CYSTEINE-RICH REPEATS; FLEXIBLE-JOINT REGION;
D O I
10.2741/3312
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PAI-1 is a M-r similar to 50,000 glycoprotein, which is the primary physiological inhibitor of the two plasminogen activators uPA and tPA. PAI-1 belongs to the serpin protein family. Studies of PAI-1 have contributed significantly to the elucidation of the protease inhibitory mechanism of serpins, which is based on a metastable native state becoming stabilised by insertion of the RCL into the central beta-sheet A and formation of covalent complexes with target proteases. In PAI-1, this insertion can occur in the absence of the protease, resulting in generation of a so-called latent, inactive form of the protein. PAI-1, in its active state, also binds to the extracellular protein vitronectin. When in complex with its target proteases, it binds with high affinity to endocytosis receptors of the low density receptor family.
引用
收藏
页码:1337 / 1361
页数:25
相关论文
共 232 条
[1]  
ADAMS DS, 1991, J BIOL CHEM, V266, P8476
[2]   CRYSTALLIZATION AND X-RAY-DIFFRACTION DATA OF THE CLEAVED FORM OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 [J].
AERTGEERTS, K ;
DEBONDT, HL ;
DERANTER, C ;
DECLERCK, PJ .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1995, 23 (01) :118-121
[3]   Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein [J].
Andersen, OM ;
Petersen, HH ;
Jacobsen, C ;
Moestrup, SK ;
Etzerodt, M ;
Andreasen, PA ;
Thogersen, HC .
BIOCHEMICAL JOURNAL, 2001, 357 (01) :289-296
[4]   PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - REACTIVE CENTER AND AMINO-TERMINAL HETEROGENEITY DETERMINED BY PROTEIN AND CDNA SEQUENCING [J].
ANDREASEN, PA ;
RICCIO, A ;
WELINDER, KG ;
DOUGLAS, R ;
SARTORIO, R ;
NIELSEN, LS ;
OPPENHEIMER, C ;
BLASI, F ;
DANO, K .
FEBS LETTERS, 1986, 209 (02) :213-218
[5]   RECEPTOR-MEDIATED ENDOCYTOSIS OF PLASMINOGEN ACTIVATORS AND ACTIVATOR/INHIBITOR COMPLEXES [J].
ANDREASEN, PA ;
SOTTRUPJENSEN, L ;
KJOLLER, L ;
NYKJAER, A ;
MOESTRUP, SK ;
PETERSEN, CM ;
GLIEMANN, J .
FEBS LETTERS, 1994, 338 (03) :239-245
[6]   PLASMINOGEN-ACTIVATOR INHIBITORS - HORMONALLY REGULATED SERPINS [J].
ANDREASEN, PA ;
GEORG, B ;
LUND, LR ;
RICCIO, A ;
STACEY, SN .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 68 (01) :1-19
[7]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[8]  
2-Z
[9]   The plasminogen activation system in tumor growth, invasion, and metastasis [J].
Andreasen, PA ;
Egelund, R ;
Petersen, HH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (01) :25-40
[10]   PAI-1 - A potential therapeutic target in cancer [J].
Andreasen, Peter A. .
CURRENT DRUG TARGETS, 2007, 8 (09) :1030-1041